Exagen (NASDAQ:XGN) CEO John Aballi Sells 11,430 Shares of Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 11,430 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $3.61, for a total value of $41,262.30. Following the sale, the chief executive officer directly owned 702,997 shares in the company, valued at approximately $2,537,819.17. This trade represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Exagen Stock Down 1.7%

Exagen stock traded down $0.07 during mid-day trading on Thursday, reaching $3.74. 157,237 shares of the company’s stock were exchanged, compared to its average volume of 554,825. The company has a fifty day moving average of $4.74 and a 200-day moving average of $7.94. The company has a market cap of $84.64 million, a P/E ratio of -4.07 and a beta of 1.90. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 1.35. Exagen Inc. has a twelve month low of $2.67 and a twelve month high of $12.23.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on XGN shares. TD Cowen dropped their target price on shares of Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. BTIG Research reduced their target price on Exagen from $15.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. B. Riley Financial reaffirmed a “buy” rating and set a $8.00 price target (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.43.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. FourWorld Capital Management LLC acquired a new position in shares of Exagen in the 2nd quarter valued at about $1,456,000. Citizens Financial Group Inc. RI bought a new stake in Exagen in the second quarter worth $472,000. Calamos Advisors LLC bought a new position in Exagen during the second quarter valued at about $526,000. R Squared Ltd bought a new stake in shares of Exagen during the 4th quarter worth about $111,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Exagen in the 4th quarter worth $1,520,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.